Drug Combo May Be Safe, Effective Therapy for Rare Leukemia
The Pharma Data
OCTOBER 21, 2020
The regimen chosen for the trial, conducted in Italy, included Sprycel and an immunotherapy drug called Blincyto (blinatumomab), which enlists the immune system to find and destroy cancer cells. That was followed by two to five treatment cycles of Blincyto, in an effort to wipe out the remains of the cancer.
52 
Let's personalize your content